12
Jan
2012
Posted in I - Series D, Q - 3Q11, R - NORTH EAST, X - Oncology, XX - PA
Ceptaris Therapeutics (Malvern, PA) a clinical-stage specialty pharmaceutical company focused on the treatment of mycosis fungoides, a type of cutaneous t-cell lymphoma, closed a $14.4M Series D financing. Participants include Vivo Ventures, Palo Alto Investors, Burrill & Co. and Aperture Venture Partners.
Thanx for your patience as we catch-up.
18
Oct
2010
15
Jul
2010
19
Jan
2010
Posted in I - Series C, Q - 4Q09, R - MID WEST, X - Oncology, X - Therapeutic Platform, XX - IN
Endocyte (West Lafayette, IN) a clinical-stage biopharmaceutical focused on folate-receptor targeted receptors in ovarian, NSCLC and breast cancers and renal cell carcinoma, closed a $26M Series B financing. Participants include Sanderling Ventures, Burrill & Co., American Bailey Ventures, Blue Chip Venture Co. and Triathlon Medical Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.
30
Oct
2009
Posted in I - Series C, Q - 3Q09, R - NORTH EAST, X - Antiinfective, X - Device (Diagnostic), XX - MA
PrimeraDx (Mansfield, MA) a development-stage molecular diagnostics company focused on automated multiplexed assays of infectious disease testing in immune compromised patients undergoing solid organ and bone marrow transplant, closed a $20M Series C financing. Participants include CHL Medical Partners, Abingworth, InterWest Partners, Malaysian Technology Development Corporation, MPM Capital, Burrill & Co. and Invus.